Rheumer Has It: Weight, GLP-1 and Arthritis

They also discuss safe, realistic strategies that support joint health, including tailored exercise and strength training, plus the emerging evidence on GLP-1 medications (like semaglutide/Ozempic/Wegovy) for people with obesity and arthritis. The key message: obesity is a treatable chronic condition, and care should be compassionate, individualized, and evidence-based.

*Content note/ trigger warning: This episode includes discussion of body weight, obesity, BMI, and weight-loss medications (including GLP-1 drugs). We approach this topic from a stigma-free, evidence-based perspective, as well as lived experience, but we know conversations about weight can be sensitive or activating, especially for those with a history of weight stigma, eating disorders, or body image challenges. Listener discretion encouraged.

Episode at a glance:

• Weight and arthritis: inflammation + joint load (OA and inflammatory arthritis)
• Why adipose tissue can worsen pain and disease activity
• BMI limits: muscle loss, fat distribution, and rheumatoid cachexia
• Exercise myth-busting: movement helps when it’s tailored and gradual
• Strength training for knee support and better joint mechanics
• GLP-1 medications (semaglutide, tirzepatide): what research shows so far
• Stigma-free framing: obesity is chronic, not a personal failure
• Practical next steps and trusted resources (Arthritis Research Canada webinar)

Medical disclaimer:

All content found on Arthritis Life public channels (including Rheumer Has It) was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Episode Sponsors

Rheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.